Navigation Links
Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update
Date:6/15/2009

on of such activities, the Company now expects its IND filing to occur within approximately six months of the previously anticipated date of July 31, 2009. The success of upcoming program efforts, including the remaining GMP scale-up production activities, the outcome of its upcoming pre-IND meeting and the outcome of the remaining non-clinical pharmacology and toxicology studies will ultimately determine the timing of Helix's Phase I/II IND/CTA filings.

Topical Interferon Alpha-2b Product Development Update - Cervical Displasia Indication ("LSIL")

During the quarter, Helix received regulatory approval to conduct its European Phase II pharmacokinetic study in human subjects prior to initiating its planned Phase IIb/III trials, and enrollment in the study is actively underway.

In parallel with its clinical progress, Helix has continued to advance its GMP production activities in anticipation of the Phase IIb and III trials in the United States and Europe respectively. Although all activities in preparation for the planned Phase IIb/III trials are progressing, the Company has experienced some delays associated with the GMP manufacturing scale-up program and in initiating the human pharmacokinetic study.

Helix is preparing to conduct a pre-IND meeting with the FDA to confirm its pivotal efficacy trial plans. Helix has submitted its formal meeting request, and is awaiting a reply from the authority confirming their timing availability. The outcome of this meeting along with the success of Helix's remaining GMP manufacturing scale-up and human pharmacokinetic study activities, will determine the timing of Helix's U.S. IND filing which was previously anticipated by July 31, 2009 but is now not expected before the end of Helix's fiscal 2010 first quarter ending October 31, 2009. The new expected timing of filing the confirmatory European Phase III Clinical Trial Application has not yet been establish
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. Helix BioPharma reports Q2 2008 highlights, financial results
11. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014 Amgen (NASDAQ: ... Directors today declared a $0.61 per share dividend for ... paid on Sept. 5, 2014, to all stockholders of ... 14, 2014.  About Amgen Amgen is ... suffering from serious illnesses by discovering, developing, manufacturing and ...
(Date:7/25/2014)... According to a new market report published ... Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 ... at USD 161,056.5 million in 2014 and is expected ... to 2020, to reach an estimated value of USD ... is witnessing a significant growth due to the increasing ...
(Date:7/25/2014)... , July 25, 2014  Galmed Pharmaceuticals Ltd. ... company focused on the development and commercialization of a ... and cholesterol gallstones, today announced financial results for the ... 2014 Financial Summary: , Reported cash and cash ... with $137,000 at December 31, 2013.  , Reported ...
(Date:7/24/2014)... July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the ... randomized, active control Phase 3 study of Zerenex (ferric ... for the treatment of hyperphosphatemia in patients with end-stage ... binding and iRon delivery with FErric CiTrate in EsrD) ... the American Society of Nephrology ( JASN ). ...
Breaking Biology Technology:Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4
... BEIJING , May 10 /PRNewswire-Asia-FirstCall/ -- Yongye International, Inc.,(Nasdaq: ... Shengmingsu brand plant and animal nutrient products in the,People,s Republic of ... four investment conferences in May 2010 . , ... The date, time and ...
... BEIJING , May 10 /PRNewswire-Asia-FirstCall/ -- Yongye International, Inc.,(Nasdaq: ... distributor of Shengmingsu brand plant and animal nutrient products in ... has started,the construction of a new production facility in Wuchuan County, ... , , ...
... ... LASIK Surgeons launched its revolutionary Trusted LASIK Surgeons directory service and website ... seeking to improve their vision and find a highly qualified eye surgeon ... sets the Trusted LASIK Surgeons directory apart is a unique screening process ...
Cached Biology Technology:Yongye International to Present at Upcoming Investor Conferences 2Yongye International to Present at Upcoming Investor Conferences 3Yongye International, Inc. Begins Construction of New Production Facility 2Yongye International, Inc. Begins Construction of New Production Facility 3Yongye International, Inc. Begins Construction of New Production Facility 4Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 2Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 3Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 4Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 5Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 6Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 7Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 8Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 9
(Date:7/27/2014)... RESEARCH UK scientists at Barts Cancer Institute have found ... cancer therapy significantly more effective, according to research published ... Barts Cancer Institute, part of Queen Mary University of ... kinase (FAK), signals the body to repair itself after ... DNA. When the researchers removed FAK from blood vessels ...
(Date:7/25/2014)... 25, 2014 In the first broad-scale estimate of air ... and collaborators calculated that trees are saving more than ... of acute respiratory symptoms. , While trees, pollution removal ... than 1 percent, the impacts of that improvement are ... reduced air pollution at nearly $7 billion every year ...
(Date:7/25/2014)... been raging this summer and some of the smoke from ... this image collected by the Moderate Resolution Imaging Spectroradiometer (MODIS) ... of smoke has descended over the Great Lakes region of ... fire image from July 23, 2014 (first image feature highlighted ... drifts off southeastward. In the image, it is over ...
Breaking Biology News(10 mins):New drug target can break down cancer's barrier against treatment 2First national study finds trees saving lives, reducing respiratory problems 2
... Sheng Yang He, plant biologist at Michigan State ... plant scientists as part of a $75 million new ... Institute and the Gordon and Betty Moore Foundation honored ... and 14 other researchers from around the country. The ...
... Spring Harbor, N.Y. The Howard Hughes Medical Institute (HHMI) ... selected Professor Rob Martienssen, Ph.D., of Cold Spring Harbor ... basic research in fundamental plant science. Dr. Martienssen is ... scientists who have been named HHMI-GBMF Investigators in plant ...
... Md. (June 16, 2011) Coaches, physiologists and athletes ... before athletic competition. Warming up increases muscle temperature, accelerates ... which enhance performance. However, the question of how long ... with some in the sports community advocating longer warm-ups ...
Cached Biology News:MSU plant scientist named one of the nation's most innovative researchers 2CSHL professor Rob Martienssen receives prestigious appointment as HHMI-GBMF investigator 2CSHL professor Rob Martienssen receives prestigious appointment as HHMI-GBMF investigator 3CSHL professor Rob Martienssen receives prestigious appointment as HHMI-GBMF investigator 4When warming up for the cycling race, less is more 2When warming up for the cycling race, less is more 3
Request Info...
IHC Detection Kit (Broad Spectrum AEC)....
... Dissociation Buffers are membrane-filtered isotonic and ... agents and cell-conditioning agents in either ... solution or Ca2+- and Mg2+-free ... mammalian cells from support substrates and ...
Request Info...
Biology Products: